The Economic Lens: Understanding what makes the EU attractive for Life Sciences Investments

Bruno Montanari, a partner at Seroba, was happy to participate in this initiative unveiled by FTI Consulting and EUCOPE as an investors perspective, during this pivotal moment for Europe as recently stressed in the Mario Draghi report.

This report provides an analysis of the current environment in the EU for attracting life sciences investments and examining the potential influence of the General Pharmaceutical Legislation on investors’ confidence and industry growth.

Some key findings include:

• Investors consider the EU as attractive for early stage investments in promising science due in large part do the world class academic research and innovation.
• The existing EU’s regulatory system for orphan medicinal products (OMPs) is seen as favorable.
• For life sciences investors in the EU, regulatory and incentives’ predictability—especially concerning OMPs—is paramount. A number of the proposals in the General Pharmaceutical Legislation risk undermining the predictability of the current system and impacting investment decisions.
• Limited availability and access to capital in the EU remains a major barrier to investment in later stage clinical programmes. The availability of capital has implications for how launches are determined and growth of the companies.

• It also aims to draw up a series of recommendations to enhance the EU’s attractiveness for Life Sciences investments and to improve access to innovative medicines in Europe.

To read the full report, please follow this link.